IASLC 2018

Adding the checkpoint inhibitor atezolizumab to chemotherapy prolonged overall survival significantly better than chemotherapy alone in patients with ES-SCLC.

When it comes to progression-free survival, patients appeared to fare better with brigatinib than they did with crizotinib, although the phase 3 trial has not yet concluded.

Following up on favorable data in 2017 on progression-free survival, a phase 3 trial on durvalumab validated its PFS benefit and added an overall survival benefit.

A retrospective study suggested that 60 Gy of neoadjuvant concomitant image-guided radiotherapy is safe and effective in locally advanced NSCLC.

In the phase 1/2 ECHO-202/KEYNOTE-037 trial, IDO1 inhibitor epacadostat plus pembrolizumab demonstrated antitumor activity in a NSCLC cohort.

Results from Phase 1 expansion cohorts showed that cemiplimab has antitumor activity against relapsed/refractory NSCLC and a safety profile similar to other PD-1 inhibitors.

A 10-year updated analysis of a phase 3 trial demonstrated that use of prophylactic cranial irradiation in NSCLC prolonged disease-free survival, but not overall survival.